Tarsus Pharmaceuticals, Inc. Overview
Pro stress-test →Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on development and commercialization of therapeutic candidates for eye care, with lead product XDEMVY for treating Demodex blepharitis and meibomian gland disease. The company has achieved exceptional commercial traction, reaching >$100M in quarterly sales within two years of launch.
Strategic Profile
Pro stress-test →Expanded market access and international regulatory initiatives support top-line growth, while strong patient demand and favorable demographic trends drive sustainable revenue expansion through multi-product pipeline development. Beyond XDEMVY, the company is developing TP-04 for ocular rosacea, TP-05 for Lyme disease prophylaxis, and expanding lotilaner applications in infectious disease.
Competitive Landscape
Pro stress-test →Tarsus operates in the ophthalmology market with XDEMVY as the only FDA-approved treatment for Demodex blepharitis. The broader eye care market includes competitors in dry eye disease (Allergan's Restasis, Bausch + Lomb's Xiidra) and related conditions. The company's first-to-market advantage in a significant unmet need provides a competitive moat, though pipeline efficacy and adoption rates will determine long-term competitive positioning.
Industry Context
Tarsus Pharmaceuticals, Inc. operates in Ophthalmology / Specialty Pharmaceuticals.
Key facts
Founded: 2016 · Headquarters: Irvine, California · Revenue: $119M quarterly (Q3 2025) · Market cap: $3.4B